uri icon
  • Contact Info
  • 202-994-8050

Laureano D. Asico Faculty Member

My early researches on dopamine and hypertension were started when I first joined the nephrology group. The research was aimed to determine the role of dopamine and its isoforms on blood pressure and natriuresis by using animal models with emphasis on its developmental influence in the young. This was also the infancy of transgenic animal technology. We determined that negation of individual dopamine isoforms resulted in the development of an elevated blood pressure. Further studies determined factors that influenced the cause of this hypertension which we then narrowed down to renal and extra-renal (nervous) influences. This advent of the creation of the transgenic animal model opened the doors to isolate the specific causes of hypertension and eliminate the confounding effects of other extraneous factors. My additional training on rodent renal cardiac and renal transplantation greatly added to the results we obtained from this study. Rapid development and advances in available technology opened more opportunity to refine methods of data collection from pharmacological agonists and antagonists of specific dopamine isoforms. Telemetry became the gold standard in blood pressure data collection from conscious animal models which eliminated the confounding effects of anesthesia. New and specific pharmacological drugs also became available which further narrowed the specific influence of specific genes. The influence of reactive oxygen species was also being investigated at this time. Progress in gene therapy and the use of siRNA technology presented another effective and economical method of duplicating disease conditions even long after the individual has come into existence. Development of advanced confocal and live imaging also presented a method through which the distribution of the active and non-active genetic plasmids can be traced as they course inside the body. Packaging of these organ and tissue specific siRNA with AAV plasmids also further refined the targeting and specificity of these gene manipulating conjugates. Tail vein injection to introduce these conjugates used to be the routine method routinely used. I have recently developed several surgical techniques through which these specific plasmids can be introduced into intended targets. I initially developed the renal subcapsular via the use of micro-osmotic pumps method coupled with modified infusion catheters to target a specific kidney. This pump was filled with the AAV9 siRNA conjugated that was mixed with an in vivo delivery system. Another method I devised for the mouse was patterned after what was originally used in larger rodents and involves the introduction of the AAV9 conjugates via the renal retro-ureteral approach. Currently, I am now actively using this to perform a gene “rescue” of knockout transgenic or siRNA infused animals.

Research Areas

GW Expert Finder utilizes up to four primary sources that shares data to populate individual profiles. Reference these FAQs for information on how to update your GW expert profile.
GW Expert Finder utilizes up to four primary sources that shares data to populate individual profiles. Reference these FAQs for information on how to update your GW expert profile.